Your cart is currently empty!
Dr. Beverly Lundell joined NAMSA in March 2025 after the acquisition of WuXi AppTec’s U.S. Medical Device Testing operations. She had been with WuXi AppTec since 2010 and now serves as Scientific Director, Custom Studies.
With a distinguished career in biomedical science, Dr. Lundell specializes in preclinical study design, regulatory compliance, and innovative testing methods. She has developed over 600 study designs, authored regulatory study reports, and pioneered in vivo and in vitro testing methods. Her work focuses on reducing animal use in testing, enhancing biocompatibility assessments, and advancing toxicological risk assessment.
Dr. Lundell holds a Ph.D. in microbiology, immunology, and cancer biology from the University of Minnesota, as well as a master’s degree in nutrition-metabolic research from the same institution and a bachelor’s degree in medical technology from Augsburg College.
